ASH 2021 | Updates in DLBCL from ASH 2021
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares some of the most exciting data in diffuse large B-cell lymphoma (DLBCL) presented at ASH 2021. To begin with, three randomized clinical trials compared chimeric antigen receptor (CAR) T-cell therapy to standard of care (SOC) in the second-line setting. The TRANSFORM (NCT03575351) and the ZUMA-7 (NCT03391466) trials reported positive results while the BELINDA trial (NCT03570892) did not meet its primary endpoint. Nevertheless, these trials suggest CAR-T therapy as a new potential SOC in the second-line setting. In addition, there were some updates in treatments for high-risk DLBCL in the first-line setting. According to Dr Kamdar, the focus now should be on moving immunotherapy earlier in the treatment of patients with high-risk DLBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
